Jazz Pharmaceuticals plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JAZZ research report →
Companywww.jazzpharma.com
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer.
- CEO
- Renee D. Gala
- IPO
- 2007
- Employees
- 2,800
- HQ
- Dublin, IE
Price Chart
Valuation
- Market Cap
- $15.03B
- P/E
- 502.61
- P/S
- 3.39
- P/B
- 3.27
- EV/EBITDA
- 47.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 84.12%
- Op Margin
- 11.13%
- Net Margin
- 0.66%
- ROE
- 0.71%
- ROIC
- -0.62%
Growth & Income
- Revenue
- $4.27B · 4.88%
- Net Income
- $-356,148,000 · -163.58%
- EPS
- $-5.84 · -164.46%
- Op Income
- $224.42M
- FCF YoY
- -3.77%
Performance & Tape
- 52W High
- $242.18
- 52W Low
- $105.00
- 50D MA
- $199.97
- 200D MA
- $163.00
- Beta
- 0.27
- Avg Volume
- 1.01M
Get TickerSpark's AI analysis on JAZZ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | COZADD BRUCE C | sell | 6,000 |
| Apr 1, 26 | COZADD BRUCE C | sell | 3,684 |
| Apr 1, 26 | COZADD BRUCE C | sell | 2,292 |
| Apr 1, 26 | COZADD BRUCE C | sell | 24 |
| Mar 5, 26 | COZADD BRUCE C | other | 15,114 |
| Mar 5, 26 | Johnson Philip L | other | 2,615 |
| Mar 5, 26 | Henderson Mary Elizabeth | other | 1,394 |
| Mar 5, 26 | Pearce Samantha | other | 2,503 |
| Mar 5, 26 | Iannone Robert | other | 6,209 |
| Mar 5, 26 | Carr Patricia | other | 1,436 |
Our JAZZ Coverage
We haven't published any research on JAZZ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate JAZZ Report →